First Trust Advisors
MAZE

First Trust Advisors’s Maze Therapeutics MAZE Stock Holding History

First Trust Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
46,227
+20,742
+81% +$544K ﹤0.01% 2130
2026
Q1 		$761K Buy
+25,485
New +$1.12M ﹤0.01% 2248

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

First Trust Advisors's MAZE Position: Q2 2026 in Review

First Trust Advisors increased its Maze Therapeutics (MAZE) stake by 81% in Q2 2026, buying an estimated $544K and bringing the position to 46,227 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2130.

First Trust Advisors first reported a position in MAZE in Q1 2026 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • First Trust Advisors held 46,227 shares of Maze Therapeutics worth $1.38M as of Q2 2026.
  • First Trust Advisors bought 20,742 Maze Therapeutics shares in Q2 2026, an estimated $544K.
  • Maze Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #2130 holding.
  • First Trust Advisors first reported a position in Maze Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.